Key result
Elevated asymmetric dimethylarginine (ADMA) is associated with endothelial dysfunction, coronary artery disease severity, and adverse cardiovascular outcomes.
Why the study?
Because atherosclerosis remains a leading cause of morbidity and mortality worldwide, identifying markers associated with its incidence and prognosis constitutes an appealing prospect.
Is asymmetric dimethylarginine (ADMA) associated with coronary artery disease incidence, severity, and prognosis?
Is asymmetric dimethylarginine (ADMA) associated with coronary artery disease incidence, severity, and prognosis?
ADMA is a promising biomarker for endothelial dysfunction and adverse cardiovascular outcomes across various stages of coronary artery disease.
No takes yet. Share an insight, caveat, or question.
ADMA may aid CAD risk stratification; leaves open whether targeting it improves outcomes.
Παπαγεωργίου et al. (2022) conducted a review in Coronary Artery Disease. Asymmetric dimethylarginine (ADMA) was evaluated. Elevated asymmetric dimethylarginine (ADMA) is associated with endothelial dysfunction, coronary artery disease severity, and adverse cardiovascular outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: